Work Here?
Singular Genomics
Work Here?
Biotechnology company advancing genomic sequencing
Singular Genomics
Work Here?
Biotechnology company advancing genomic sequencing
About Singular Genomics
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Total Funding
$44.3M
Headquarters
San Diego, California
Founded
2016
Overview
Singular Genomics focuses on advancing the field of genomics, which involves studying the complete set of DNA in organisms. The company provides tools and technologies for genomic sequencing, helping clients like academic researchers, pharmaceutical companies, and clinical laboratories conduct multiomic research that examines various biological data types, including DNA, RNA, and proteins. Their main product, the G4 sequencing platform, is designed for ultra-high throughput and high-resolution spatial sequencing, allowing researchers to process multiple samples at once, which enhances the efficiency of large-scale genomic studies. Singular Genomics differentiates itself from competitors by offering a high-performance sequencing system that supports complex biological research. The company's goal is to accelerate scientific and medical research by providing advanced sequencing technologies that aid in understanding and treating complex diseases.
Simplify's Take
What believers are saying
- The G4X Spatial Sequencer attracts research institutions for high-resolution genomic studies.
- Significant revenue growth from expanding the installed base and new consumable kits.
- Partnership with Tecan automates NGS library preparation, streamlining workflows.
What critics are saying
- Integration challenges with Deerfield Management post-acquisition could disrupt operations.
- Non-binding acquisition proposal from Concentra Biosciences may cause stakeholder uncertainty.
- Competitive pressure on the G4X Spatial Sequencer from established market players.
What makes Singular Genomics unique
- Singular Genomics offers a unique multiomics solution with the PX Integrated Solution.
- The G4 Sequencing Platform provides ultra-high throughput and high-resolution spatial sequencing.
- Partnerships with companies like Fluent Biosciences enhance scalability and cost-effectiveness.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$44.3M
Above
Industry Average
Funded Over
2 Rounds
Coatue ManagementGrowth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 1%Singular Genomics Systems (Nasdaq: OMIC) has agreed to be acquired by Deerfield Management Company for $20 per share in an all-cash transaction, representing a 254% premium over the last closing price before Deerfield's initial proposal on September 12, 2024. The deal, expected to close in the first half of 2025, will take Singular Genomics private. The transaction requires stockholder approval but is not subject to financing conditions.
SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC) (“Singular Genomics” or the “Company”), a company leveraging...
The non-binding acquisition proposal from Concentra Biosciences to acquire Singular Genomics for $12.00 per share in cash represents a significant premium to the current stock price.
Singular Genomics unveils groundbreaking G4X Spatial Sequencer.
Attributing this remarkable increase to the company's strategic expansion of its installed base of instruments, Singular Genomics also acknowledged the launch of two new consumable kits - the F3 flow cells and Max Read flow cells - as a contributing factor.
There are no jobs for Singular Genomics right now.
Find jobs on Simplify and start your career today
About Singular Genomics
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Total Funding
$44.3M
Headquarters
San Diego, California
Founded
2016
There are no jobs for Singular Genomics right now.
Find jobs on Simplify and start your career today